[go: up one dir, main page]

FR3062570B1 - Composition pharmaceutique anti-angiogenese contenant un pentadepsipeptide cyclique en tant que composant efficace - Google Patents

Composition pharmaceutique anti-angiogenese contenant un pentadepsipeptide cyclique en tant que composant efficace Download PDF

Info

Publication number
FR3062570B1
FR3062570B1 FR1851006A FR1851006A FR3062570B1 FR 3062570 B1 FR3062570 B1 FR 3062570B1 FR 1851006 A FR1851006 A FR 1851006A FR 1851006 A FR1851006 A FR 1851006A FR 3062570 B1 FR3062570 B1 FR 3062570B1
Authority
FR
France
Prior art keywords
angiogenesis
effective component
nmssv
present
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1851006A
Other languages
English (en)
Other versions
FR3062570A1 (fr
Inventor
Chan Lee
Sung-Kwon Moon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Chung Ang University
Original Assignee
Industry Academic Cooperation Foundation of Chung Ang University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180011886A external-priority patent/KR102022631B1/ko
Application filed by Industry Academic Cooperation Foundation of Chung Ang University filed Critical Industry Academic Cooperation Foundation of Chung Ang University
Publication of FR3062570A1 publication Critical patent/FR3062570A1/fr
Application granted granted Critical
Publication of FR3062570B1 publication Critical patent/FR3062570B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une composition pour l'inhibition de l'angiogenèse, contenant du néo-N-méthylsansalvamide (NMSSV), qui est un pentadepsipeptide cyclique, en tant que composant efficace, et spécifiquement, puisque le NMSSV de la présente invention présente une activité excellente qui inhibe la migration cellulaire et la formation des tubes associées à l'angiogenèse, et inhibe d'une façon dépendante de la concentration l'angiogenèse induite par un facteur de croissance de l'endothélium vasculaire, on s'attend à ce que le NMSSV de la présente invention puisse inhiber l'angiogenèse et être utilisé de façon utile en tant qu'agent thérapeutique pour diverses maladies dans lesquelles l'angiogenèse est régulée anormalement.
FR1851006A 2017-02-09 2018-02-07 Composition pharmaceutique anti-angiogenese contenant un pentadepsipeptide cyclique en tant que composant efficace Active FR3062570B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020170018103 2017-02-09
KR20170018103 2017-02-09
KR1020180011886 2018-01-31
KR1020180011886A KR102022631B1 (ko) 2017-02-09 2018-01-31 고리형 펜타뎁시펩타이드를 유효성분으로 함유하는 혈관신생 억제용 약학적 조성물

Publications (2)

Publication Number Publication Date
FR3062570A1 FR3062570A1 (fr) 2018-08-10
FR3062570B1 true FR3062570B1 (fr) 2021-03-12

Family

ID=62948404

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1851006A Active FR3062570B1 (fr) 2017-02-09 2018-02-07 Composition pharmaceutique anti-angiogenese contenant un pentadepsipeptide cyclique en tant que composant efficace

Country Status (2)

Country Link
FR (1) FR3062570B1 (fr)
WO (1) WO2018147615A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102170939A (zh) * 2008-05-22 2011-08-31 卡鲁斯治疗有限公司 酯肽及其治疗用途
KR101120565B1 (ko) * 2009-01-02 2012-03-09 중앙대학교 산학협력단 신규 고리형 펜타뎁시펩타이드(ⅰ) 및 그 이용
KR101119561B1 (ko) * 2009-01-02 2012-03-07 중앙대학교 산학협력단 고리형 펜타뎁시펩타이드를 생산하는 푸사리움속 미생물
WO2011081229A1 (fr) * 2009-12-29 2011-07-07 이화여자대학교 산학협력단 Composition pharmaceutique pour l'inhibition de l'angiogenèse

Also Published As

Publication number Publication date
WO2018147615A1 (fr) 2018-08-16
FR3062570A1 (fr) 2018-08-10

Similar Documents

Publication Publication Date Title
MA52486B1 (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA46269B1 (fr) Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r
MA47399B1 (fr) Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
MA52219B1 (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
MA40434B1 (fr) 1-((3s,4r)-4-(3-fluorophényl)-1-(2-méthoxyéthyl)pyrrolidin-3-yl)-3-(4-méthyl-3-(2-méthylpyrimidin-5-yl)-1-phényl-1h-pyrazol-5-yl)urée comme inhibiteur de la kinase trka
EA202090932A1 (ru) Способы введения некоторых vmat2-ингибиторов
MA39219A1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
EA201800499A1 (ru) Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор
FR3126511B1 (fr) « Ressort d’horlogerie en alliage de titane β métastable, et son procédé de fabrication »
MA44206A (fr) Comprimé orodispersible comprenant estetrol
EP3345613A4 (fr) Composition pharmaceutique contenant, comme principe actif, une protéine de fusion dans laquelle un peptide pénétrant les tumeurs et un agent antiangiogenèse sont fusionnés, pour la prévention et le traitement du cancer ou de maladies associées à l'angiogenèse
MX2021002935A (es) Formulacion de anticuerpos contra csf-1r.
MA42701B1 (fr) Compositions d'insuline à action rapide
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
CL2021000683A1 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
MA46548B1 (fr) Fsh pour le traitement de l'infertilité
MA61732A1 (fr) Ouvreur de canaux potassiques sensibles à la tension destiné à être utilisé dans le traitement de l'anhédonie
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
FR3062570B1 (fr) Composition pharmaceutique anti-angiogenese contenant un pentadepsipeptide cyclique en tant que composant efficace
MA49839B1 (fr) Inhibiteurs bicycliques de la histone déacétylase
MA45639B1 (fr) Combinaison d'antagonistes purs du récepteur 5-ht6 avec des inhibiteurs d'acétylcholinestérase
CO2024017422A2 (es) Composiciones y métodos para inhibir la expresión de serina proteasa transmembrana 6 (tmprss6)
EP3603647A4 (fr) Composition pharmaceutique pour la prévention et le traitement du glaucome, contenant un dérivé d'adénosine
WO2018199854A3 (fr) Dispositifs de dimensionnement et d'élimination de l'appendice auriculaire gauche et procédés associés

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 3

PLSC Publication of the preliminary search report

Effective date: 20200619

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8